

Marcos de Lima

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6495754/publications.pdf>

Version: 2024-02-01

59
papers

938
citations

623188

14
h-index

500791

28
g-index

65
all docs

65
docs citations

65
times ranked

1097
citing authors

#	ARTICLE	IF	CITATIONS
1	NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 16-27.	2.3	170
2	A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Advances, 2020, 4, 5580-5588.	2.5	122
3	Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplantation, 2018, 53, 449-456.	1.3	92
4	Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia, 2019, 33, 2599-2609.	3.3	76
5	Single cell RNA sequencing of AML initiating cells reveals RNA-based evolution during disease progression. Leukemia, 2021, 35, 2799-2812.	3.3	41
6	Cardiovascular Events Associated with Chimeric Antigen Receptor T Cell Therapy: Cross-Sectional FDA Adverse Events Reporting System Analysis. Biology of Blood and Marrow Transplantation, 2020, 26, 2211-2216.	2.0	40
7	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Advances, 2022, 6, 339-357.	2.5	35
8	Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients. Nature Communications, 2021, 12, 7200.	5.8	31
9	Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin Lymphoma. Cancer Discovery, 2022, 12, 1886-1903.	7.7	31
10	Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. Leukemia, 2021, 35, 2076-2085.	3.3	28
11	Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplantation, 2019, 54, 1281-1286.	1.3	24
12	Conditioning regimen intensity and low-dose azacitidine maintenance after allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Leukemia and Lymphoma, 2020, 61, 2839-2849.	0.6	19
13	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Advances, 2020, 4, 3180-3190.	2.5	18
14	AML and the art of remission maintenance. Blood Reviews, 2021, 49, 100829.	2.8	18
15	Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis. Bone Marrow Transplantation, 2022, 57, 911-917.	1.3	18
16	Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries. Cancer Medicine, 2021, 10, 3862-3872.	1.3	17
17	Cardiovascular risk assessment and management of patients undergoing hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 544-551.	1.3	16
18	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. Bone Marrow Transplantation, 2021, 56, 3068-3077.	1.3	13

#	ARTICLE	IF	CITATIONS
19	Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents. <i>Bone Marrow Transplantation</i> , 2019, 54, 497-507.	1.3	11
20	Thioredoxin reductase is a major regulator of metabolism in leukemia cells. <i>Oncogene</i> , 2021, 40, 5236-5246.	2.6	11
21	A Phase I Study to Determine the Maximum Tolerated Dose of ex Vivo Expanded Natural Killer Cells Derived from Unrelated, HLA-Disparate Adult Donors. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 250.e1-250.e8.	0.6	10
22	Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy. <i>Radiology</i> , 2022, 302, 438-445.	3.6	9
23	Racial and age-related disparities in early mortality affect the outcomes of multiple myeloma patients. <i>Leukemia</i> , 2021, 35, 250-254.	3.3	8
24	Refractory inflammatory myopathy in hematopoietic stem cell transplant patients with chronic graft-versus-host disease: report of two cases. <i>Hematology, Transfusion and Cell Therapy</i> , 2019, 41, 268-271.	0.1	7
25	Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 2811-2820.	0.6	7
26	Targeted dose of busulfan: Higher risk of sinusoidal obstructive syndrome observed with systemic exposure dose above 5000 $\mu\text{Mol}\cdot\text{min}$. A historically controlled clinical trial. <i>Hematological Oncology</i> , 2020, 38, 773-781.	0.8	6
27	Interrogating the impact of KIR ligand mismatch in engraftment following HLA-disparate stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 2294-2297.	1.3	6
28	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2108-2117.	1.3	6
29	Assessment of Salvage Regimens Post-Chimeric Antigen Receptor T Cell Therapy for Patients with Diffuse Large B Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 342.e1-342.e5.	0.6	5
30	Pharmacokinetics analysis results are similar for oral compared to intravenous busulfan in patients undergoing hematopoietic stem cell transplantation, except for the earlier onset of mucositis. A controlled clinical study. <i>Bone Marrow Transplantation</i> , 2019, 54, 1799-1804.	1.3	4
31	BAFF receptor antibody for mantle cell lymphoma therapy. <i>Oncolmmunology</i> , 2021, 10, 1893501.	2.1	4
32	Timing Embryo Preservation for a Patient with High-Risk Newly Diagnosed Acute Myeloid Leukemia. <i>Case Reports in Hematology</i> , 2018, 2018, 1-3.	0.3	3
33	Cryopreservation of hematopoietic cells using a pre-constituted, protein-free cryopreservative solution with 5% dimethyl sulfoxide. <i>Cytotherapy</i> , 2020, 22, 613-616.	0.3	3
34	Socio-Economic Burden of Myocardial Infarction Among Cancer Patients. <i>American Journal of Cardiology</i> , 2021, 141, 16-22.	0.7	3
35	A Pilot Phase I Trial of IL-21 Expanded Ideal-Donor Natural Killer (NK) Cells in Combination with Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas (CTCL) or Adult T-Cell Leukemia/Lymphomas (ATLL). <i>Blood</i> , 2021, 138, 1388-1388.	0.6	3
36	COVID-19 presenting as a viral exanthem and detected during admission prescreening in a hematopoietic cell transplant recipient. <i>Hematology, Transfusion and Cell Therapy</i> , 2020, 42, 215-217.	0.1	2

#	ARTICLE	IF	CITATIONS
37	Efficacy and cost-benefit of filgrastim administered after early assessment bone marrow biopsy during induction therapy for acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1450-1457.	0.6	2
38	A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Universally Alloreactive Donor-Derived Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2021, 138, 1732-1732.	0.6	2
39	Pre-Infusion Neurofilament Light Chain (NfL) Levels Predict the Development of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) - a Multicenter Retrospective Study. <i>Blood</i> , 2021, 138, 2841-2841.	0.6	2
40	Sequential Single Cell Transcriptional and Protein Marker Profiling Reveals Tigit As a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin's Lymphoma. <i>Blood</i> , 2021, 138, 164-164.	0.6	2
41	Treatment-related mortality following autologous hematopoietic stem cell transplantation is unaffected by timing of G-CSF administration. <i>Bone Marrow Transplantation</i> , 2020, 55, 1697-1700.	1.3	1
42	Significant costs and low utilization of stored peripheral blood stem cells for salvage autologous transplant in multiple myeloma patients including those meeting mSMART criteria. <i>Bone Marrow Transplantation</i> , 2021, 56, 1458-1461.	1.3	1
43	Prompt CR Plus Consolidation Therapy Yields Improve Survival after Allogeneic Transplantation for AML Patients Receiving Myeloablative, but Not Reduced-Intensity Conditioning: A CIBMTR Analysis. <i>Blood</i> , 2021, 138, 414-414.	0.6	1
44	Cardiac Arrhythmias and Mortality after Hematopoietic Stem Cell Transplant (HSCT): A Systematic Review and Meta-Analysis. <i>Blood</i> , 2021, 138, 2918-2918.	0.6	1
45	Post-Transplant Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 2899-2899.	0.6	1
46	Romidepsin in Conditioning and Maintenance Mitigates Relapse Risk and Enhances NK-Cell Cytotoxicity in Patients Receiving Allogeneic Stem Cell Transplant for Aggressive T-Cell Malignancies: Results of a Phase I/II Clinical Trial. <i>Blood</i> , 2021, 138, 553-553.	0.6	1
47	Outcomes of Large B-Cell Lymphoma Patients By Post CAR-T Salvage Regimen at a Single Institution. <i>Blood</i> , 2021, 138, 3851-3851.	0.6	1
48	Going home for the holidays? Take a shortcut!. <i>Bone Marrow Transplantation</i> , 2017, 52, 514-515.	1.3	0
49	Improving patient access to modern myeloma therapy in Latin America: first step, know what your problem really is. <i>Leukemia and Lymphoma</i> , 2020, 61, 3033-3034.	0.6	0
50	History of drug use in allogeneic hematopoietic cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2021, 56, 581-585.	1.3	0
51	Rapid manufacture of cd19 car t cells in an automated system for treatment of non-hodgkin lymphoma results in long term persistence in vivo. <i>Cytotherapy</i> , 2021, 23, S85-S86.	0.3	0
52	Utilizing Organ-Sparing Marrow Irradiation to Condition Patients Prior to Allogeneic Hematopoietic Cell Transplant with High-Risk Hematologic Malignancies: Results of a Pilot Study. <i>Blood</i> , 2021, 138, 2856-2856.	0.6	0
53	Final Results of a Phase 1 Study of AntiCD19 CAR-T Cells with TNFRSF19 Transmembrane Domain. <i>Blood</i> , 2021, 138, 3833-3833.	0.6	0
54	Effect of Age on Outcomes of Allogeneic Transplantation in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2021, 138, 3933-3933.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Next-Generation Sequencing to Assess the Impact of Low Dose Melphalan on Residual Disease before High-Dose Melphalan and Stem Cell Transplant in Multiple Myeloma. <i>Blood</i> , 2021, 138, 4933-4933.	0.6	0
56	A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Third-Party Donor-Derived Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S220.	0.6	0
57	Bamlanivimab Monoclonal Antibody Treatment in Patients with Graft Versus Host Disease (GVHD) Diagnosed with COVID-19 Infection. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S386-S387.	0.6	0
58	Allogenic Transplantation in Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S115-S116.	0.6	0
59	Outcomes of Salvage Therapy after Failure of Anti-CD19 CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S183-S184.	0.6	0